A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey

Boğa, İbrahim; Sağ, Şebnem Özemri; Duman, Nilgun; Ozdemir, Sevda Yesim; Ergoren, Mahmut Cerkez; Dalcı, Kubilay; Mujde, Cem; Parsak, Cem Kaan; Rencuzogullari, Cagla; Sonmezler, Ozge; Yalav, Orçun; Alemdar, Adem; Aliyeva, Lamiya; Bozkurt, Özlem; Çetintaş, Sibel Kahraman; Çubukçu, Erdem; Deligonul, Adem; Dogan, Berkcan; Erguzeloglu, Cemre Ornek; Evrensel, Türkkan; Gokgoz, Sehsuvar; Şenol, Kazım; Tolunay, Şahsine; Akyurek, Esra; Basgoz, Neslihan; Gökçe, Nuriye; Dundar, Bilge; Öztürk, Figen; Taskin, Duygu; Demirtas, Mercan; Cag, Murat; Diker, Ömer; Bozdogan, Sevcan Tug; Dündar, Munis; Bişgin, Atıl; Temel, Şehime Gülsün

doi:10.4274/ejbh.galenos.2023.2023-2-5

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BRCA1 : BRCA2 PV ratio was determined to be 1:1.5. In three different studies performed with the Turkish BC population, the BRCA1 : BRCA2 PV ratios were found to be 1:2, 36 1:1.5, 37 and 1.3:1, 38 respectively. In two unrelated patients carrying a PV in the BRCA1 gene, a heterozygous deletion in exons 18–19 was detected.…”

Section: Discussionmentioning

confidence: 99%

BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients

Alavanda,

Dirimtekin,

Mortoglou

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) persists as the predominant malignancy globally, standing as the foremost cause of cancer-related mortality among women. Despite notable advancements in prevention and treatment, encompassing the incorporation of targeted immunotherapies, a continued imperative exists for the development of innovative methodologies. These methodologies would facilitate the identification of women at heightened risk, enhance the optimization of therapeutic approaches, and enable the vigilant monitoring of emergent treatment resistance. Circulating microRNAs (miRNAs), found either freely circulating in the bloodstream or encapsulated within extracellular vesicles, have exhibited substantial promise for diverse clinical applications. These applications range from diagnostic and prognostic assessments to predictive purposes. This study aimed to explore the potential associations between BRCA mutations and specific miRNAs (miR-21, miR-155, miR-126, and miR-200c) expression that are known to be dysregulated in BC patient samples. Our findings indicate a robust correlation between miRNA expression status and disease subtypes. We found a correlation between the expression status of miRNAs and distinct disease subtypes. Intriguingly, however, no significant associations were discerned between disease status, subtypes, or miRNA expression levels and the presence of BRCA mutations. To advance the validation of miRNAs as clinically relevant biomarkers, additional investigations within larger and meticulously selected patient cohorts are deemed imperative. These microRNA entities hold the potential to emerge as groundbreaking and readily accessible tools, poised for seamless integration into the landscape of clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%